Core Viewpoint - BeiGene (06160.HK) announced the grant of restricted stock units to 375 participants under its 2016 option and incentive plan, totaling 34,361 American Depositary Shares, equivalent to 446,693 shares, representing approximately 0.03% of the company's total issued shares as of the announcement date [1] Summary by Category - **Company Actions** - The board's compensation committee granted restricted stock units to 375 participants [1] - The total number of restricted stock units granted is 34,361 [1] - **Shareholder Impact** - The granted units are equivalent to 446,693 shares [1] - This represents about 0.03% of the total issued shares of the company as of the announcement date [1]

智通财经APP讯，百济神州(06160)公布，于2025年8月8日，董事会薪酬委员会根据2016期权及激励计划 的条款向375名承授人授出涉及合共34,361股美国存托股份的受限制股份单位。 ...

Core Viewpoint - BeiGene Limited (06160) announced the grant of restricted stock units involving a total of 34,361 American Depositary Shares to 375 grantees on August 8, 2025, under the terms of the 2016 option and incentive plan [1] Summary by Relevant Categories - **Company Actions** - The company granted a total of 34,361 restricted stock units to 375 individuals [1] - This action is part of the 2016 option and incentive plan [1] - **Future Implications** - The issuance of restricted stock units may align the interests of employees with those of shareholders, potentially enhancing company performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年8月8日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向三百七十五名承授人授出涉 及合共34,361股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2025年8月8日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予三百七 十五名承授人合共34,361股美國存託股份受限制股份單位。該等受限制股份單位 相當於446,693股股份，約佔本公告之日公司發行股份總數的0.03%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2025年8月8日 承授人數目： 三百七十五名 已授出受限制股份單位涉及 的相關股份數目： 446,693 受 ...

Core Viewpoint - BeiGene (06160) shares rose over 4%, reaching 187.2 HKD with a trading volume of 341 million HKD, following the announcement of the initiation of a Phase III clinical trial for its PD-1 inhibitor, Tislelizumab, for specific cancer treatment [1] Company Summary - The Phase III clinical trial for Tislelizumab is aimed at treating locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy as first-line therapy [1] - Tislelizumab is BeiGene's core product, which has been approved in 47 markets globally [1] - Since its launch in 2019, Tislelizumab has been utilized in treating key cancer types such as urothelial carcinoma and non-small cell lung cancer, benefiting millions of patients worldwide [1] - In the first half of 2025, Tislelizumab generated sales of 2.643 billion CNY, reflecting a year-on-year growth of 20.6% [1]

Group 1 - The core viewpoint of the article highlights the positive impact of rising expectations for interest rate cuts in the US on the biotechnology sector, leading to a significant increase in the S&P Biotechnology Index by 2.89% [1] - The Hong Kong pharmaceutical sector continues to show strong performance, with the Hong Kong Pharmaceutical ETF (159718.SZ) rising by 0.38% [1] - Notable individual stock performances include a 6.22% increase for Simcere Pharmaceutical Group (02410), a 3.34% rise for BeiGene (06160), and a 2.29% increase for Kelun-Biotech (06990) [1] Group 2 - The liquidity in the market is robust, with the Hong Kong Pharmaceutical ETF seeing a turnover of 13.3% and a transaction volume of 36.42 million yuan within the first 20 minutes of trading [1] - Guotai Junan Securities has stated that China's innovative drugs are on the rise, entering the initial phase of realizing innovation results, with significant opportunities for independent development and large transactions through business development (BD) licensing [1] - The Hong Kong Pharmaceutical ETF focuses on 18 A-share biotechnology companies, including key innovative drug firms such as BeiGene, WuXi Biologics, and CSPC Pharmaceutical Group, benefiting from global innovation drug research dividends [1] Group 3 - The article emphasizes the favorable conditions for the innovative drug growth sector due to the anticipated US interest rate cuts, which are expected to benefit the domestic innovative drug companies as they expand internationally [1] - The recommendation is to pay attention to the Hong Kong Pharmaceutical ETF (159718.SZ) and its associated funds (Class A: 019598, Class C: 019599) as they are positioned to capitalize on these trends [1]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) has seen a strong increase of 1.38% as of August 14, 2025, with notable gains from companies such as BeiGene (4.45%), Lepu Biopharma (2.87%), and China Resources Pharmaceutical (2.26%) [3] - The Hong Kong Innovative Drug Selected ETF (520690) rose by 1.60%, with a latest price of 1.01 yuan, and has accumulated a 1.01% increase over the past two weeks, ranking in the top half among comparable funds [3] - The trading volume for the Hong Kong Innovative Drug Selected ETF was 12.42 million yuan, with a turnover rate of 3.1% [3] Group 2 - BeiGene has initiated a Phase III clinical trial for its PD-1 inhibitor, Tislelizumab, for use in combination with chemotherapy for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [4] - In its Q2 2025 earnings report, BeiGene reported total revenue of 17.518 billion yuan, a year-on-year increase of 46.0%, and a net profit of 450 million yuan, marking its first half-year profit [4] - BeiGene has raised its full-year revenue forecast for 2025 to a range of 35.8 billion to 38.1 billion yuan, with an expected gross margin improvement to the mid-high range of 80% to 90% [4] Group 3 - The National Healthcare Security Administration has announced the preliminary review of the drug list for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance, which includes innovative drugs [5] - The introduction of the commercial insurance innovative drug list is seen as a significant development that will benefit the growth of commercial insurance and expand payment channels, contributing to the multi-tiered medical security system in China [5] - The investment strategy for the second half of 2025 emphasizes embracing innovation-driven growth, internationalization, and reforms in outpatient marketing models, particularly in the innovative drug sector [5] Group 4 - The latest size of the Hong Kong Innovative Drug Selected ETF reached 395 million yuan, marking a new high since its inception [5] - Over the past two weeks, the ETF has seen a significant increase of 70 million shares, ranking in the top half among comparable funds [5] Group 5 - The Hong Kong Innovative Drug Selected ETF experienced a net outflow of 6.8698 million yuan recently, but has seen net inflows on four out of the last five trading days, totaling 40.2103 million yuan [6] - The maximum drawdown since the ETF's inception is 5.45%, with a relative benchmark drawdown of 0.11% [6] - The management fee for the ETF is 0.50%, and the custody fee is 0.10%, which are among the lowest in comparable funds [6] Group 6 - As of August 13, 2025, the top ten weighted stocks in the HSSCPB index account for 78% of the index, including BeiGene, Innovent Biologics, and WuXi Biologics [7] - The Hong Kong Innovative Drug Selected ETF aims to capture opportunities in the development of China's innovative drug industry [7]

Group 1 - The core viewpoint of the news is that Minsheng Asset recently conducted research on BeiGene, highlighting the company's growth prospects and market expansion strategies [1] - BeiGene's product, Baiyueze, has seen a moderate single-digit percentage increase in net pricing in the U.S. and aims to maintain price stability throughout the year [1] - Baiyueze has been approved in 75 markets, while Baizean has received approval in 47 markets, indicating a strong global regulatory expansion strategy [1] Group 2 - The revenue guidance adjustment is based on Baiyueze's leading position in the U.S. market and the ongoing expansion in Europe and other markets, suggesting a diversification of revenue structure [1] - Gross margin growth is attributed to improved production efficiency of Baiyueze and Baizean, with considerations for tariff policy impacts [1] - The ORR data from the BRUIN CLL-314 study lacks statistical significance, while the ALPINE study shows Baiyueze's superiority over Ibrutinib [1] Group 3 - The BTK CDAC is being explored for applications in immunology and inflammation, with a long half-life, penetrative properties, and degradation characteristics [1] - The initiation of the Phase III trial for the CDK4 inhibitor has been postponed to early 2026, with plans to release dose optimization data this year, indicating a positive market outlook for breast cancer treatment [1] - The Phase III clinical trial for BTK CDAC is expected to start in the second half of 2025, with pivotal Phase II trials and registration submissions planned for 2026 [1]

Group 1 - Ming Shi Partners Fund recently conducted research on BeiGene, indicating that the net price of Baiyueze in the U.S. has seen a mid-single-digit percentage increase, with price stability expected throughout the year [1] - Baiyueze has been approved in 75 markets, while Baizean has received approval in 47 markets, with plans for continued global regulatory expansion [1] - The U.S. remains the largest market, with rapid growth in Europe and other regions, leading to a diversified revenue structure [1] Group 2 - Revenue guidance adjustments are based on Baiyueze's leading position in the U.S. and ongoing expansion in Europe and other markets [1] - Gross margin growth is attributed to improved production efficiency of Baiyueze and Baizean, taking tariff policy impacts into account [1] - The ORR data from the BRUIN CLL-314 study lacks statistical significance, while the ALPINE study shows Baiyueze outperforming Ibrutinib [1] Group 3 - BTK CDAC is being explored for applications in immunology and inflammation, with a long half-life, penetrative properties, and degradation characteristics [1] - The Phase III trial for CDK4 inhibitors has been postponed to early 2026, with plans to release dose optimization data this year, indicating a positive market outlook for breast cancer treatment [1] - The Phase III clinical trial for BTK CDAC is expected to start in the second half of 2025, with pivotal Phase II trials and registration submissions planned for 2026 [1]

Group 1: Baiji Shenzhou - Baiji Shenzhou reported a moderate single-digit percentage increase in the net price of Baiyueze in the U.S., with plans to maintain price stability throughout the year [1] - Baiyueze has been approved in 75 markets, while Baizean has received approval in 47 markets, indicating ongoing global regulatory expansion [1] - The revenue guidance adjustment is based on Baiyueze's leading position in the U.S. and rapid growth in Europe and other markets, with a diversified revenue structure expected [1] - Gross margin growth is attributed to improved production efficiency of Baiyueze and Baizean, considering the impact of tariff policies [1] - The ORR data from the BRUIN CLL-314 study lacks statistical significance, while the ALPINE study shows Baiyueze outperforming Ibrutinib [1] - BTK CDAC is being explored for applications in immunology and inflammation, with a Phase III clinical trial expected to start in the second half of 2025 [1] - The initiation of the Phase III trial for CDK4 inhibitors has been postponed to early 2026, with dose optimization data to be released this year [1] Group 2: Aladdin - The Aladdin platform operates independently of the Chinese Academy of Sciences, with a wide business coverage and a registered membership of 247,000 [2] - The platform has over 1,800 research institutions and 10,218 suppliers, with an annual transaction volume nearing 4 billion yuan [2] - Revenue sources include store fees, bridge fees, value-added services, and advertising fees, with 2023 profits boosted by non-recurring income [2] - A decline in profits for 2024 is not attributed to core business operations [2] - The company has completed six investment deals across various sectors and will continue to seek new projects [2]